Getting your player ready...
AspenBio Pharma Inc. said additional data analysis following a recent clinical trial likely will result in a delayed application for Food and Drug Administration clearance of its test for acute appendicitis.
Shares slumped 54 percent, $1.81, to close at $1.57 in Nasdaq trading Monday.
The Castle Rock-based pharmaceutical startup had expected to submit its application by late this month for the blood- based test, known as AppyScore.
